公开(公告)号：US10774154B2

公开(公告)日：2020-09-15

申请号：US15846686

申请日：2017-12-19

Applicant: MORPHOSYS AG

Inventor： Stefan Haertle ,  Christian Frisch ,  Achim Knappik

IPC: C07K16/42 ,  C07K16/24 ,  G01N33/68

Abstract: The present invention provides antibodies and fragments thereof that specifically detect the complex of a specific cognate antigen-binding moiety, in particular antibodies, and its antigen. The antibodies of the present disclosure do not bind either said cognate antigen binding moiety or said antigen alone and this can be used e.g. to directly detect antigen-bound antigen-binding moieties. Further disclosed are methods for production and use of said antibodies and antibody fragments.

公开(公告)号：US20200223904A1

公开(公告)日：2020-07-16

申请号：US16624514

申请日：2018-06-21

Applicant: MORPHOSYS AG

Inventor： Thomas Tiller ,  Markus Waldhuber ,  Ralf Strohner ,  Kathrin Ladetzki-Baehs ,  Josef Prassler

IPC: C07K16/00 ,  C07K16/18

Abstract: The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries.

公开(公告)号：US20200206228A1

公开(公告)日：2020-07-02

申请号：US16806353

申请日：2020-03-02

Applicant: MORPHOSYS AG

Inventor： Jan ENDELL ,  Rainer BOXHAMMER ,  Mark WINDERLICH

IPC: A61K31/519 ,  C07K16/28 ,  A61P35/00 ,  A61K47/68 ,  A61K39/395

Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor and its use for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

公开(公告)号：US10604566B2

公开(公告)日：2020-03-31

申请号：US15764918

申请日：2016-10-05

Applicant: MORPHOSYS AG ,  GALAPAGOS NV

Inventor： Nick Ernest René Vandeghinste ,  Reginald Christophe Xavier Brys

IPC: C07K16/24 ,  A61K39/395 ,  A61K31/573 ,  A61K45/06 ,  C07K14/54 ,  A61K39/00

Abstract: The present invention provides antagonists of IL-17C for use in the treatment and/or prevention of atopic dermatitis and related conditions.

公开(公告)号：US20190322742A1

公开(公告)日：2019-10-24

申请号：US16310555

申请日：2017-06-27

Applicant: MorphoSys AG

Inventor： Patrick Garidel ,  Andreas Langer ,  Martin Hessling ,  Daniel Weinfurtner ,  Bodo Brocks

IPC: C07K16/28 ,  A61K9/19 ,  A61K31/715 ,  A61K47/36 ,  A61K47/54

Abstract: The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody.

公开(公告)号：US20190202906A1

公开(公告)日：2019-07-04

申请号：US16286231

申请日：2019-02-26

Applicant: MORPHOSYS AG ,  GALAPAGOS NV

Inventor： Jan Dominik HAAS ,  Jürgen Klattig ,  Nick Ernest Rene Vandeghinste

IPC: C07K16/24 ,  C12N15/62

CPC classification number: C07K16/244 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/62

Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.

公开(公告)号：US20190048071A1

公开(公告)日：2019-02-14

申请号：US16076401

申请日：2017-02-17

Applicant: MORPHOSYS AG ,  GALAPAGOS NV

Inventor： Jan Dominik HAAS ,  Jürgen KLATTIG ,  Nick Ernest René VANDEGHINSTE

IPC: C07K16/24 ,  C12N15/62

Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.

公开(公告)号：US20180153892A1

公开(公告)日：2018-06-07

申请号：US15572914

申请日：2016-05-25

Applicant: MORPHOSYS AG

Inventor： Jan Endell ,  Rainer Boxhammer ,  Mark Winderlich

IPC: A61K31/519 ,  A61K39/395 ,  A61K47/68 ,  C07K16/28 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K39/39558 ,  A61K47/68 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/732 ,  A61K2300/00

Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

公开(公告)号：US20180022823A1

公开(公告)日：2018-01-25

申请号：US15670811

申请日：2017-08-07

Applicant: MORPHOSYS AG

Inventor： LISA ROJKJAER ,  RAINER BOXHAMMER ,  JAN ENDELL ,  MARK WINDERLICH ,  CHRISTOFER SAMUELSSON

IPC: C07K16/40 ,  A61K31/69 ,  A61K38/05 ,  A61K39/395 ,  C07K16/30 ,  A61K31/454 ,  A61K45/06 ,  C07K16/28 ,  A61K38/07 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K31/454 ,  A61K31/69 ,  A61K38/05 ,  A61K38/07 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2896 ,  C07K16/3061 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  A61K2300/00

Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.

公开(公告)号：US09758590B2

公开(公告)日：2017-09-12

申请号：US14958980

申请日：2015-12-04

Applicant: MorphoSys AG

Inventor： Michael Tesar ,  Ute Jaeger

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/00 ,  C12N9/24 ,  C07K16/40 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K16/005 ,  C07K16/3061 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/92 ,  C07K2319/30 ,  C12N9/2497 ,  C12Y302/02024

Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.